secwatch.observer — SEC 8-K summary
======================================

Issuer:     NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
CIK:        0001979414
Form:       8-K
Filed at:   2026-07-15T13:15:28+00:00
Accession:  0001829126-26-007585
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NeOnc receives FDA written feedback on NEO212 CMC development; cancels Type B meeting
--------------------------------------------------------------------------------

- FDA provided detailed CMC feedback for NEO212, a temozolomide-perillyl alcohol conjugate for CNS cancers.
- FDA stated NeOnc's CMC approach appears reasonable; additional comparative assessments may be needed if process changes.
- FDA allowed parallel CMC development with late-stage clinical program, subject to supporting data.
- FDA requires an in vivo relative bioavailability study to support capsule-to-tablet transition.
- NeOnc canceled the July 9 Type B End-of-Phase 1 meeting after determining written responses were sufficiently clear.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626007585/0001829126-26-007585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1979414/000182912626007585/neonctechnologies_8k.htm
  HTML page:      https://secwatch.observer/filing/0001829126-26-007585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer